The Galleri™ test detected cancer signals across more than 50 cancer types, most of which do not have current guideline-recommended screenings.1,4
In approximately 200 people tested, only 1 person would be expected to receive a false positive result.
The Galleri test’s low risk of false positives minimizes unnecessary diagnostic testing and patient anxiety.
In participants with cancer, when the Galleri test detected cancer, its prediction of the cancer signal origin was correct 89% of the time.
Predicting the origin of the cancer signal helps healthcare providers select the appropriate follow-up diagnostics tests or procedures to confirm the diagnosis.
76.3% sensitivity in cancers that cause two-thirds of cancer deaths in the US 1,6,7
Different cancers shed DNA into the bloodstream at different rates.8 The proportion of tumor-derived cfDNA in the blood tends to increase as cancer progresses. Cancers that shed more DNA at earlier stages tend to be associated with higher mortality.9 The greater the proportion of cfDNA in a sample, the stronger its signal and the more likely it is to be detected by the Galleri test.5
The cancer types specified here account for 63% of all estimated cancer deaths.6,7 The Galleri test detected a cancer signal in approximately 3 out of 4 people with one of the cancers in this high-signal cancer group.1
Learn more about the clinical studies building clinical evidence for the Galleri test.
Clinical evidence supporting the development and validation of the Galleri test has been described in peer-reviewed publications.
View FAQs for more information about the Galleri test performance and results.